XENETIC BIOSCIENCES, INC. Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net
XENETIC BIOSCIENCES, INC. (XBIO) had Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net of -$379.25 thousand as of 2014-01-23, per its 10-Q filed 2014-11-14.
Discontinued › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less)
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet · last filed 2014-11-14
- 2014-01-23: Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net -$379.25K.
| Period end | Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net |
|---|---|
| 2014-01-23 | -$379.25K 10-Q · filed 2014-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |